Latest news

Galecto Raises $64 Million to Accelerate Development of Clinical Pipeline

Galecto, Inc., a privately-held biotechnology company focused on the development of novel treatments for fibrosis and cancer, announced today the successful completion of a $64 million equity financing. This reinforces Galecto’s existing cash balance extending the Company’s cash runway into late 2022.

Galecto’s Oral Galectin-3 Inhibitor GB1211 Well Tolerated in Phase I Clinical Data Presented Recently at Several Scientific Conferences

Galecto, Inc., a privately-held biotechnology company focused on the development of novel treatments for fibrosis and cancer, announced today that its  potent and selective oral small molecule galectin-3 inhibitor, GB1211, was well tolerated in pre-clinical and Phase 1 studies and is ready to start a Phase 2a clinical study to treat liver fibrosis in Non-Alcoholic SteatoHepatitis (NASH).

Galecto, Inc. Receives U.S. and EU Orphan Drug Designations for GB0139 in Idiopathic Pulmonary Fibrosis

Galecto, Inc., a privately-held biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced it has received Orphan Drug Designation (ODD) from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for GB0139 in the treatment of Idiopathic Pulmonary Fibrosis (IPF).

Galecto Appoints New Chair and Strengthens Board of Directors

Galecto, Inc., a privately-held biotechnology company focused on the development of novel treatments for fibrosis and cancer, announced today that its Board of Directors has appointed Amit Munshi as its new Chairman. Galecto also announced the appointment of David Shapiro MD, the former Chief Medical Officer of Intercept Pharmaceuticals, to its Board of Directors.

Galecto Advances Phase 2b Study of GB0139 in Idiopathic Pulmonary Fibrosis; Recruitment Remains on Track Despite COVID-19 Crisis

Galecto, Inc., a privately-held biotechnology company focused on the development of novel treatments for fibrosis and cancer, announced today that it has recruited more than 150 patients in its Phase 2b GALACTIC-1 study of GB0139 in Idiopathic Pulmonary Fibrosis (IPF).

Preclinical and clinical evidence for antifibrotic activity of Galecto's lead compound, GB0139 (formerly TD139), contained in an abstract for the Experimental Biology 2020 conference

The poster presentation, available online as the conference was canceled due to COVID-19, described results from preclinical studies investigating galectin-3 in vitro and in vivo in naïve and bleomycin‐treated mice.

Galecto presents GB0139 preclinical and clinical data on anti-fibrotic activity as online Experimental Biology 2020 poster

Galecto, Inc., a privately-held biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced new data describing the preclinical and clinical evidence for anti-fibrotic activity of its lead compound GB0139 (formerly TD139), in an abstract for the Experimental Biology 2020 conference.

Galecto Appoints Jonathan Freve as Chief Financial Officer

Galecto, Inc., a privately-held biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced the appointment of Jonathan Freve, CPA, as its Chief Financial Officer (CFO).

Galecto Appoints Industry Leader Bertil Lindmark, MD, PhD, as Chief Medical Officer

Galecto, Inc., a leading developer of novel treatments for fibrosis  and cancer, today announces the appointment of the highly experienced industry leader Bertil Lindmark as Chief Medical Officer per February 1, 2020.